SCHEMBL23905892

SCHEMBL23905892

COC(=O)c1cc(C)c(N)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.49
KDM4E B2RXH2 5/20 0.47
POLB P06746 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
GAA P10253 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
LMNA P02545 1/20 0.44
NFKB1 P19838 1/20 0.44
XDH P47989 1/20 0.44
GFER P55789 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
FUT7 Q11130 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10683847 0.89 KDM4E (0.53) CNR2KDM4EPOLBMAPTALDH1A1
SCHEMBL5787161 0.87 CA12 (0.54) CNR2KDM4EPOLBMAPTALDH1A1
SCHEMBL30418756 0.84 KDM4E (0.53) CNR2KDM4EPOLBMAPTALDH1A1
SCHEMBL13681473 0.84 LMNA (0.58) ALDH1A1CA12CA1CA2CA7
SCHEMBL22458580 0.84 CA12 (0.58) CNR2KDM4EPOLBALDH1A1CA12
SCHEMBL18031417 0.84 KDM4E (0.53) CNR2KDM4EPOLBMAPTALDH1A1
SCHEMBL22458784 0.84 TSHR (0.53) ALDH1A1CA12CA1CA2CA7
SCHEMBL26579774 0.82 KDM4E (0.58) CNR2KDM4EPOLBMAPTALDH1A1
SCHEMBL637391 0.81 KDM4E (0.53) CNR2KDM4EPOLBMAPTALDH1A1
SCHEMBL18969524 0.81 KMT2A (0.51) CNR2KDM4EPOLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 US disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed
WO-2021198981-A1 ANTIVIRAL COMPOUNDS AND USES THEREOF Janssen Biopharma, Inc. (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD1, SLC29A1, ENTPD5 CNR2 450/4885KDM4E 2852/4885POLB 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.